Drug Information of Lasmiditan and Its Effectiveness for Maigraine

  • Abdul Mustaq Mohammed Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.
  • Nayak S P Srinivas Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.
  • Safi Ur-Rahman Mohammed Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.
  • Muneb Ahmed Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India

Abstract

Migraine is the leading cause of disability in people under 50 years of age and the second highest cause of disability worldwide with significant impact on the daily lives of patients and their families, 50-200mg lasmiditan is a serotonin (5-HT) 1F receptor agonist new class of medication needed for treatment of migraine, A latest drug with recent studies showns to be efficacious and safe for the prevention of migraine in adults, Lasmiditan was more effective than placebo for the acute treatment of migraine in patients concurrently using migraine preventive medications. Lasmiditan efficacy and safety measures were similar for patients using and not using preventive medications.


 

Keywords: lasmiditan, maigraine, efficacy of lasmiditan.

Downloads

Download data is not yet available.

Author Biographies

Abdul Mustaq Mohammed, Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.

Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.

Nayak S P Srinivas, Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.

Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.

Safi Ur-Rahman Mohammed, Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.

Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India.

Muneb Ahmed, Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India

Department of Pharmacy Practice, Sultan-ul-Uloom College of pharmacy, Hyderabad, Telangana, India

References

1. Migraine Research Foundation. About migraine: migraine facts. Updated December 10, 2019. Accessed June 5, 2020. 2019 https://migraineresearchfoundation.org/about-migraine/migraine-facts.
2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
3. Steiner TJ, Stovner LJ, Vos T et al (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 19:17.2018/02/23. https://doi.org/10.1186/s10194-018-0846-2.
4. Collaborators GDaIIaP (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259. 2017/09/19. https://doi.org/10.1 016/S0140-6736(17)32154-2.
5. Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349. 2007/ 01/31. https://doi.org/10.1212/01.wnl.0000252808.97649.21
6. Silberstein SD, Holland S, Freitag F et al (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78: 1337–1345. 2012/04/25. https://doi.org/10.1212/WNL.0b013e3182535d20
7. Silberstein SD (2015) Preventive Migraine Treatment. Continuum (Minneap Minn) 21:973–989. 2015/08/08. https://doi.org/10.1212/CON. 0000000000000199
8. Evers S, Afra J, Frese A et al (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16:968–981. 2009/08/28. https://doi.org/10.1111/j.1468-1331.2009.02748.x
9. Kline GS. Imitrex: Highlights of Prescribing Information, https://www. accessdata.fda.gov/drugsatfda_docs/label/2012/020132s024s026lbl.pdf (2017, Accessed 10 Mar 2019)
10. Nelson DL, Phebus LA, Johnson KW et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30: 1159–1169. 2010/09/22. https://doi.org/10.1177/0333102410370873
11. Tfelt-Hansen PC. History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia. 2010;30(7):780-792.
12. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174-182.
13. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.
14. Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555-567.
15. Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48(8):856-866.
16. Dodick DW. Migraine. Lancet. 2018;391(10127):1315-1330.
17. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol.2015;14(1):65-80.
18. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193.
19. Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77:281.
20. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54.
21. Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):274-290.
22. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol. 2002;59(7):1084-1088.
23. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26.
24. Bernice Kuca et al Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study Neurology 2018;91:e2222-e2232
25. Loo et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials. The Journal of Headache and Pain (2019) 20:84
26. Deborah Tepper MD, FAHS Lasmiditan for the acute treatment of migraine First published: 31 May 2020 https://doi.org/10.1111/head.13798
Statistics
20 Views | 25 Downloads
How to Cite
Mohammed, A., Srinivas, N., Mohammed, S., & Ahmed, M. (2020). Drug Information of Lasmiditan and Its Effectiveness for Maigraine. Asian Journal of Pharmaceutical Research and Development, 8(5), 140-142. https://doi.org/https://doi.org/10.22270/ajprd.v8i5.818